OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018

 
OHE Director Adrian Towse, OHE Director of Research Nancy Devlin, OHE Visting Senior Research Fellow Lou Garrison and Patricia Danzon, of the Wharton School and a member of OHE’s Research and Policy Committee presented at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare held on October 19, 2018 in Washington DC. 
 
In the session “Specific value assessment considerations” Adrian Towse presented on Indication Based Pricing:  A better way to value drugs? setting out the arguments for and against differential pricing by indication. This built on work from an OHE consulting report and research report.
 

 
Patricia Danzon presented in the same session on Affordability: When is it a concern? This picked up on her paper for the ISPOR US Value Special Task Force and her paper for the Value-in-Health Themed Session on Affordability, setting out how budget pressures should be handled in theory and practice, and the related issues of cures and paying for drugs for small populations. 
 

 
In another session Lou Garrison introduced Novel approaches to value assessment, within the cost-effectiveness framework drawing on the overall findings of the ISPOR US Value Special Task Force.
 

 
Nancy Devlin presented as part of this session on Extending the scope of patient reported outcomes and QALYs, in which she set out some of the limitations of the QALY and set out the objectives of a new project Extending the QALY, led by SCHARR, which intends to developing a broad measure of quality of life for use in economic evaluations across health and social care.
 

 
Related research:
 
Berdud, M., Drummond, M., & Towse, A. (2018). Establishing a Reasonable Price for an Orphan Drug. OHE Research Paper 18/05, London: Office of Health Economics. Available at: https://www.ohe.org/publications/establishing-reasonable-price-orphan-drug#.
 
Cole, A., Towse, A., Lorgelly, P. and Sullivan, R. (2018). Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper 18/04, London: Office of Health Economics. Available at: https://www.ohe.org/publications/economics-innovative-payment-models-comparedsingle-pricing-pharmaceuticals#overlay-context=publications.
 
Danzon P. Affordability challenges to value-based pricing: mass diseases, orphan diseases, and cures. Value Health 2018;21:252–7. Available at: https://www.valueinhealthjournal.com/article/S1098-3015(18)30032-9/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301518300329%3Fshowall%3Dtrue.
 
Danzon, P.M, Drummond, M. Towse, A., Pauly, MV. (2018) Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4] Value in Health, Vol. 21, Issue 2, p140–145DOI: https://doi.org/10.1016/j.jval.2017.12.008; Published in February 2018.
 
Garrison, L.P., Neumann, P.J., Wilkie, R.J., Basu, A., Danzon, P.M., Doshi, J.A., Drummond, M.F., Lakdawalla, D.N., Pauly, M.V., Phelps, C.E., Towse, A. and Weinstein, M.C., 2018. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 21(2), pp.161-165. DOI: https://doi.org/10.1016/j.jval.2017.12.009
 
Karlsberg-Schaffer, S., Messner, D., Mestre-Ferrandiz, J., Tambor, E. and Towse, A., 2018. Paying for Cures: Perspectives on Solutions to the “Affordability Issue”. Value in Health, 21(3), pp.76-279. DOI: https://doi.org/10.1016/j.jval.2017.12.013
 
Towse, A., Cole, A., and Zamora, B. (2018). The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries. OHE Consulting Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/debate-indicationbased-pricing-us-and-five-major-european-countries.
 
Towse, A. and Mauskopf. 2018, Affordability of New Technologies: The Next Frontier, Value in Health. DOI: https://doi.org/10.1016/j.jval.2018.01.011.

 

Posted in Health Technology Assessment, Pricing and Reimbursement, Research | Tagged External publications